FORM 8-K/A
    


                       SECURITIES AND EXCHANGE COMMISSION


                             Washington, D.C. 20549



                                 CURRENT REPORT


                    Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934



         Date of Report (Date of earliest event reported): June 3, 1998




                             MEDTOX SCIENTIFIC, INC.
             (Exact name of registrant as specified in its charter)


                                    Delaware
                 (State or other jurisdiction of incorporation)


1-11394                                                              95-3863205
(Commission File Number)                      (IRS Employer Identification No.)


402 West County Road D
St. Paul, Minnesota                                                       55112
(Address of principal executive offices)                             (Zip Code)


                                 (612) 636-7466
              (Registrant's telephone number, including area code)









Item 4.  Change In Independent Accountants



   
     Effective May 27, 1998, the Registrant  terminated Ernst & Young LLP as its
independent  accounting  firm. The termination of Ernst & Young LLP was approved
by the Audit Committee of the Board of Directors of the Registrant.

    Ernst & Young LLP's report on the financial statements of the Registrant for
each of the last two fiscal  years  neither  contained  an adverse  opinion or a
disclaimer of opinion,  nor was qualified or modified as to  uncertainty,  audit
scope, or accounting principles.

     During the Registrant's two most recent fiscal years and the interim period
through May 27, 1998, there were no  disagreements  or "reportable  events" with
Ernst & Young LLP as described in Items 304(a)(1)(iv) and (v) of Regulation S-K.
     
     Accordingly,  Ernst & Young LLP has not advised the  Registrant  of (i) the
absence  of the  internal  controls  necessary  for the  Registrant  to  develop
reliable  financial  statements,  (ii) any information which would cause Ernst &
Young LLP to no longer  rely on  management's  representations,  or that Ernst &
Young LLP was unwilling to be associated with the financial  statements prepared
by management, (iii) any need to expand significantly the scope of its audit, or
any  information  that if further  investigated  may (a)  materially  impact the
fairness  or  reliability  of either a  previously  issued  audit  report or the
underlying  financial  statements  or any  financial  statements  for any fiscal
period subsequent to the date of the most recent financial statements covered by
an  audit  report  or (b)  cause  it to be  unwilling  to rely  on  management's
representations or be associated with the Registrant's financial statements,  or
(iv) any information that has come to the attention of Ernst & Young LLP that it
concluded  materially  impacts  the  fairness  or  reliability  of either  (a) a
previously issued audit report or the underlying financial statements or (b) any
financial  statements  issued  or  to  be  issued  covering  any  fiscal  period
subsequent  to the date of the most recent  financial  statements  covered by an
audit report.

     Effective June 3, 1998, the Registrant engaged Deloitte & Touche LLP as its
independent  accounting firm.  Neither the Registrant or any of its subsidiaries
has had any prior relationships with Deloitte & Touche LLP.

     







                                   SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                            MEDTOX Scientific, Inc.




   
Date:  June 16, 1998                         By: /s/ Peter J. Heath
                                                --------------------
    

                                            Name:  Peter J. Heath
                                            Title: Vice President of Finance 
                                                   and Chief Financial Officer